Crucell, AERAS, and SATVI Announce TB Vaccine Clinical Trial
Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com), the Aeras Global TB Vaccine Foundation (Rockville, MD, www.aeras.org) and the South African Tuberculosis Vaccine Initiative (SATVI, Cape Town, South Africa, www.satvi.uct.ac.za) at the University of Cape Town, recently announced the launch of a new Phase 1 clinical trial of the AdVac-based tuberculosis vaccine, six months after launching a similar study in the US.
Dutch biotechnology company Crucell N.V. (Leiden, the Netherlands, www.crucell.com), the Aeras Global TB Vaccine Foundation (Rockville, MD, www.aeras.org) and the South African Tuberculosis Vaccine Initiative (SATVI, Cape Town, South Africa, www.satvi.uct.ac.za) at the University of Cape Town, recently announced the launch of a new Phase 1 clinical trial of the AdVac-based tuberculosis vaccine, six months after launching a similar study in the US. The trial will be conducted in the Boland-Overberg region of Western Cape Province in South Africa, which has one of the world’s highest TB burdens. Aeras and Crucell began jointly developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s AdVac vaccine technology and PER.C6 manufacturing technology.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
